Response to Pembrolizumab in a Heavily Treated Patient with Metastatic Ovarian Carcinosarcoma

Overview

Journal Gynecol Oncol Res Pract

Publisher Biomed Central

Date 2018 Aug 28

PMID 30147940

Citations 7

Authors

Graziela Zibetti Dal Molin

Carina Meira Abrahao

Robert L Coleman

Fernando Cotait Maluf

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described.

Case Presentation: A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites.

Conclusions: Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention.

Citing Articles

SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.

Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J Clin Cancer Res. 2024; 30(24):5593-5600.

PMID: 39417692 PMC: 11737520. DOI: 10.1158/1078-0432.CCR-24-0606.

Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma.

Xu J, Tu M J Zhejiang Univ Sci B. 2024; 25(8):686-699.

PMID: 39155781 PMC: 11337087. DOI: 10.1631/jzus.B2300407.

Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.

McFarlane I, Porter J, Brownsell E, Ghaoui N, Connolly K, Herrington C Front Oncol. 2024; 14:1399979.

PMID: 38854725 PMC: 11157229. DOI: 10.3389/fonc.2024.1399979.

Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.

Herrington C, Oswald A, Stillie L, Croy I, Churchman M, Hollis R Br J Cancer. 2023; 130(2):327-335.

PMID: 38097740 PMC: 10803731. DOI: 10.1038/s41416-023-02508-3.

Disparity in the era of personalized medicine for epithelial ovarian cancer.

Devlin M, Miller R Ther Adv Med Oncol. 2023; 15:17588359221148024.

PMID: 36643655 PMC: 9837277. DOI: 10.1177/17588359221148024.

References

. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014; 125(2):97-8. DOI: 10.1016/j.ijgo.2014.02.003. View

Lee J, Cimino-Mathews A, Peer C, Zimmer A, Lipkowitz S, Annunziata C . Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A.... J Clin Oncol. 2017; 35(19):2193-2202. PMC: 5493052. DOI: 10.1200/JCO.2016.72.1340. View

Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y . Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2007; 108(1):136-40. DOI: 10.1016/j.ygyno.2007.09.003. View

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T . Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015; 33(34):4015-22. DOI: 10.1200/JCO.2015.62.3397. View

Brown E, Stewart M, Rye T, Al-Nafussi A, Williams A, Bradburn M . Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004; 100(10):2148-53. DOI: 10.1002/cncr.20256. View

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English D . Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016; 113(43):12238-12243. PMC: 5087050. DOI: 10.1073/pnas.1614120113. View

Chun K, Kim J, Kim D, Kim J, Kim Y, Nam J . Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecol Obstet Invest. 2011; 72(3):208-14. DOI: 10.1159/000323775. View

Paulsson G, Andersson S, Sorbe B . A population-based series of ovarian carcinosarcomas with long-term follow-up. Anticancer Res. 2013; 33(3):1003-8. View

Dictor M . Malignant mixed mesodermal tumor of the ovary: a report of 22 cases. Obstet Gynecol. 1985; 65(5):720-4. View

10.

Shylasree T, Bryant A, Athavale R . Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev. 2013; (2):CD006246. PMC: 6756783. DOI: 10.1002/14651858.CD006246.pub2. View

11.

Mole R . Whole body irradiation; radiobiology or medicine?. Br J Radiol. 1953; 26(305):234-41. DOI: 10.1259/0007-1285-26-305-234. View

12.

DAngelo E, Prat J . Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011; 25(6):705-18. DOI: 10.1016/j.bpobgyn.2011.05.010. View

13.

Sharon E, Streicher H, Goncalves P, Chen H . Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014; 33(9):434-44. PMC: 4190433. DOI: 10.5732/cjc.014.10122. View

14.

Rauh-Hain J, Growdon W, Rodriguez N, Goodman A, Boruta 2nd D, Schorge J . Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011; 121(3):477-81. DOI: 10.1016/j.ygyno.2011.02.023. View

15.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann J, Leitao M, Powell M, Poveda A . Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S55-60. DOI: 10.1097/IGC.0000000000000228. View

16.

Ardighieri L, Mori L, Conzadori S, Bugatti M, Falchetti M, Donzelli C . Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. Virchows Arch. 2016; 469(1):61-9. DOI: 10.1007/s00428-016-1933-x. View

17.

Carmen M, Birrer M, Schorge J . Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2011; 125(1):271-7. DOI: 10.1016/j.ygyno.2011.12.418. View

18.

Webb J, Milne K, Kroeger D, Nelson B . PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016; 141(2):293-302. DOI: 10.1016/j.ygyno.2016.03.008. View

19.

Mittica G, Genta S, Aglietta M, Valabrega G . Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. Int J Mol Sci. 2016; 17(7). PMC: 4964540. DOI: 10.3390/ijms17071169. View